Medical Device, Type 2 Diabetes
Conditions
Brief summary
This is a single-center, open-label, prospective study. Blood glucose was measured at different time points during oral glucose tolerance testing in patients with type 2 diabetes mellitus, using both venous plasma and multi-channel microspatial offset Raman scattering spectroscopy (mμSORS). Venous plasma glucose was set as gold standard.The two measurements were collected synchronously so as to calculate the mean absolute relative difference (MARD) and the consensus error grid (CEG). Accuracy of non-invasive blood glucose testing by mμSORS will be validated. MARD for two measurement methods in different blood glucose ranges and the safety outcomes of mμSORS such as adverse events will also be assessed.
Detailed description
In order to clinically verify the accuracy and safety of non-invasive blood glucose measurement by the mμSORS technology, and to explore the feasibility of non-invasive detection in multi-indicators of mμSORS, this study will conduct an oral glucose tolerance test on patients with type 2 diabetes. There will be 12 collection points of blood samples as follows: 0-min and post glucose-load 15-min，30-min，45-min，60-min，75-min，90-min，105-min，120-min，135-min，150-min， and 180-min. Approximately 4ml of whole blood was collected at each time point for venous plasma glucose and serum insulin measurement. The blood glucose value measured by mμSORS will be obtained synchronously at the above 12 time points.
Interventions
Blood glucose of participants were measured by venous plasma and multi-channel microspatial offset Raman scattering spectroscopy (mμSORS). The two measurements were collected synchronously and analyzed.
Sponsors
Shanghai Photonic View Technology Co., Ltd.
Shanghai Jiao Tong University School of Medicine
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 1\. Subjects with type 2 diabetes mellitus; * 2\. Age ≥ 18 years; * 3\. There are no scars, obvious pigmentation and other factors that interfere with the detection of the palm skin to be tested; * 4\. Fully understand the nature, significance, possible benefits, possible inconveniences or potential risks of this research, and should also understand the research procedures, be willing to complete the entire research process, and provide written consent form.
Exclusion criteria
* 1\. Type 1 diabetes, monogenic diabetes, pancreatic damage, or secondary diabetes of other causes should be excluded; * 2\. Severe structural heart disease, such as congenital heart disease, rheumatic heart disease, hypertrophic or dilated cardiomyopathy, chronic congestive heart failure (NYHA≥III); acute myocardial infarction within 12 months before enrollment; history of severe liver or kidney dysfunction(MDRD eGFR\< 60 ml/min/1.73m2); and mental disorders, etc.; * 3\. With a history of acute complications of diabetes within 3 months before enrollment; or severe chronic complications of diabetes; * 4\. Alcohol dependency or drug abuse; * 5\. Those who have participated in clinical trials of other drugs within 3 months before screening (since the last visit of the previous trial); * 6\. Pregnancy or lactation period; * 7\. Difficulty in venous blood collection or blood-injection-injury phobia; * 8\. Other circumstances that the investigator considers inappropriate to participate in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean absolute relative deviation (MARD) of venous plasma glucose and glucose values measured by mμSORS at each time point of OGTT. | Four months. | Glucose will be measured using both intravenous sampling (plasma) and multi-channel microspatial offset Raman scattering spectroscopy (mμSORS) detection synchronously. |
| Consensus Error Grid (CEG) for venous plasma glucose and glucose values measured by mμSORS at each time point of OGTT. | Four months. | Glucose will be measured using both intravenous sampling (plasma) and multi-channel microspatial offset Raman scattering spectroscopy (mμSORS) detection synchronously. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| MARD for two measurement methods in different blood glucose ranges. | Four months. | Plasma glucose ranges 3.9-10.0 mmol/L, \<3.9 mmol/L and \>10.0 mmol/L. |
| Incidence of Treatment-Emergent Adverse Events | Four months. | Safety outcomes. |
Countries
China
Outcome results
None listed